The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Open accessAbstract
Cerebrospinal fluid (CSF) concentrations of amyloid-beta (Abeta) 1-38, 1-40, 1-42, total-tau and phospho-tau in samples from 156 patients with Alzheimer's disease (AD) (n = 44), depressive cognitive complainers (DCC, n = 25) and various other forms of non-Alzheimer dementias (NAD, n = 87) were analyzed by electrochemiluminescence and enzyme linked immunosorbent assay, respectively. A significant decrease of CSF Abeta1-42 was the most powerful single marker for differentiation of AD from DCC, yielding accuracies of beyond 85%. Increased p-tau and the ratio Abeta1-42/Abeta1-38 yielded accuracies of beyond 80 and 85%, respectively, to discriminate AD versus NAD. Combining p-tau with Abeta1-42/Abeta1-38 resulted in a sensitivity of 94% for detection of AD and 85% specificity for excluding NAD. Decreased CSF Abeta1-42 represents a core biomarker for AD. The lack of specificity for exclusion of NAD can be most effectively compensated by the ratio Abeta1-42/Abeta1-38. The ratio Abeta1-42/Abeta1-38/p-tau powerfully discriminates AD versus NAD and fulfils the accuracy requirements for an applicable screening and differential diagnostic AD biomarker.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, it has been shown that the levels of Aβ38, Aβ42 and the Aβ42/Aβ38 ratio in cerebral spinal fluid (CSF) can be used to distinguish AD from other dementias [32–34].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [32]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Weıntraub, S. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120075013 · Cited by 3,018
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 1×
“The major constituent of NFT’s is tau, a microtubule-associated protein that undergoes excessive phosphorylation (phosphorylated tau, p-tau) at multiple sites (e.g. p-tau199, p-tau181 and p-tau231) and aggregates into paired helical filaments in AD (Lee et al. 1991).”
BackgroundA subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 2×
“…distributions of different Ab species are regulated within very narrow limits (Wiltfang et al. 2002; Bibl et al. 2007a; Wiltfang et al. 2007) (4) Distinct g-secretase activities may be reflected most adequately by the ratio Ab1-42/Ab1-40 Wiltfang et al. 2001) or Ab1-38/Ab1-40 (Weggen et al. 2001).”
BackgroundImproved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Self-citationReduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
Blennow, K. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.2.213 · Cited by 500
Vanmechelen, E., Vanderstichele, H., Davidsson, P., Kerschaver, E. V., Perre, B. V. D., Sjögren, M. J. C., Andreasen, N. C., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 487
Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434
Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340
Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau
Lewczuk, P., Esselmann, H., Otto, M., Maler, J. M., Henkel, A. W., Henkel, M. K., Eikenberg, O., Antz, C., Krause, W., Reulbach, U., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00086-1 · Cited by 317
Self-citationWiltfang, J., Esselmann, H., Bibl, M., Av, S., Otto, M., Paul, S., Schmidt, B., Klafki, H., Maler, M., Dyrks, T., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00818.x · Cited by 274
Self-citationWiltfang, J., Esselmann, H., Bibl, M., Hüll, M., Hampel, H. J., Kessler, H., Frölich, L., Schröder, J., Peters, O., Jessen, F., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04404.x · Cited by 269
Self-citationCombination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease
Shoji, M., Matsubara, E., Kanai, M., Watanabe, M., Nakamura, T., Tomidokoro, Y., Shizuka, M., Wakabayashi, K., Igeta, Y., Ikeda, Y., et al. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00122-1 · Cited by 221
Bibl, M., Mollenhauer, B., Esselmann, H., Lewczuk, P., Klafki, H., Sparbier, K., Av, S., Cepek, L., Trenkwalder, C., Rüther, E., et al. (2006) · Brain · doi:10.1093/brain/awl063 · Cited by 212
Self-citationMaddalena, A., Papassotiropoulos, A., Müller-Tillmanns, B., Jung, H. H., Hegi, T., Nitsch, R. M., & Hock, C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1202 · Cited by 204
Lewczuk, P., Beck, G., Esselmann, H., Bruckmoser, R., Zimmermann, R., Fiszer, M., Bibl, M., Maler, J. M., Kornhuber, J., & Wiltfang, J. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.058776 · Cited by 146
Self-citationWiltfang, J., Esselmann, H., Cupers, P., Neumann, M., Kretzschmar, H. A., Beyermann, M., Schleuder, D., Jahn, H., Rüther, E., Kornhuber, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102790200 · Cited by 126
Self-citationClinical Guidelines for Idiopathic Normal Pressure Hydrocephalus
Ishikawa, M. (2004) · Neurologia medico-chirurgica · doi:10.2176/nmc.44.222 · Cited by 124
Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same?
Schoonenboom, N. S. M., Mulder, C., van Kamp, G. J., Mehta, S. P., Scheltens, P., Blankenstein, M. A., & Mehta, P. D. (2005) · Annals of Neurology · doi:10.1002/ana.20508 · Cited by 122
Lewczuk, P., Esselmann, H., Meyer, M., Wollscheid, V., Neumann, M., Otto, M., Maler, J. M., Rüther, E., Kornhuber, J., & Wiltfang, J. (2003) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1048 · Cited by 100
Self-citationde Jong, D., Jansen, R. W. M. M., Kremer, B. P. H., & Verbeek, M. M. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.7.755 · Cited by 98
Bibl, M., Esselmann, H., Otto, M., Lewczuk, P., Cepek, L., Rüther, E., Kornhuber, J., & Wiltfang, J. (2004) · Electrophoresis · doi:10.1002/elps.200305992 · Cited by 94
Self-citationValidation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias
Bibl, M., Mollenhauer, B., Lewczuk, P., Esselmann, H., Wolf, S., Trenkwalder, C., Otto, M., Stiens, G., Rüther, E., Kornhuber, J., et al. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001967 · Cited by 93
Self-citationFamilial Alzheimer's disease: Site of mutation influences clinical phenotype
Lippa, C. F., Swearer, J. M., Kane, K., Nochlin, D., Bird, T. D., Ghetti, B. F., Nee, L. E., George‐Hyslop, P. S., Pollen, D. A., & Drachman, D. A. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3 · Cited by 67
CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies
Bibl, M., Mollenhauer, B., Esselmann, H., Lewczuk, P., Trenkwalder, C., Brechlin, P., Rüther, E., Kornhuber, J., Otto, M., & Wiltfang, J. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0537-z · Cited by 66
Self-citationNew criteria for the diagnosis of vascular dementia
Drachman, D. A. (1993) · Neurology · doi:10.1212/wnl.43.2.243 · Cited by 57
The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently
Shoji, M., Kanai, M., Matsubara, E., Tomidokoro, Y., Shizuka, M., Ikeda, Y., Ikeda, M., Harigaya, Y., Okamoto, K., & Hirai, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00229-3 · Cited by 50
Progressive Supranuclear Palsy and Corticobasal Degeneration
Lessig, S., & Litvan, I. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199928453.003.0011 · Cited by 36
Progressive Supranuclear Palsy and Corticobasal Degeneration
Coughlin, D. G., Dickson, D. W., Josephs, K. A., & Litvan, I. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_11 · Cited by 33
Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations
Bibl, M., Mollenhauer, B., Wolf, S., Esselmann, H., Lewczuk, P., Kornhuber, J., & Wiltfang, J. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-006-0618-z · Cited by 33
Self-citationCerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical usefulness
Shoji, M., & Kanai, M. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3306 · Cited by 31
Bibl, M., Lewczuk, P., Esselmann, H., Mollenhauer, B., Klafki, H., Welge, V., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2008) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200800006 · Cited by 26
Self-citationCerebrospinal Fluid Neurochemical Phenotypes in Vascular Dementias: Original Data and Mini-Review
Bibl, M., Mollenhauer, B., Esselmann, H., Schneider, M., Lewczuk, P., Welge, V., Gross, M., Falkai, P., Kornhuber, J., & Wiltfang, J. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000115975 · Cited by 26
Self-citationIncreased Cerebrospinal Fluid Aβ38/Aβ42 Ratio in Alzheimer Disease
Mehta, P. D., & Pirttilä, T. (2005) · Neurodegenerative Diseases · doi:10.1159/000090363 · Cited by 24
Wills, W., Trieman, N., & Leff, J. (1998) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199804)13:4
Cited by
Sorted by citations
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383
Metadata
- Authors
- Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., Wiltfang, J., & Bibl, M.
- Affiliations
- University of Duisburg-Essen (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Göttingen (DE)
- Paracelsus Elena Klinik Kassel (DE)
- Universität Ulm (DE)
- Corresponding author
- Bibl, Mirko
- ORCID
- Venue
- Journal of Neural Transmission
- Published
- 2009-01-14
- Volume
- 116
- Issue
- 2
- Pages
- 203-212
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2041245991
- Cited by
- 152
- References
- 42
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 10 · 2023: 7 · 2022: 6 · 2021: 10 · 2020: 17 · 2019: 2 · 2018: 3 · 2017: 8 · 2016: 5 · 2015: 13 · 2014: 14 · 2013: 13 · 2012: 10
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion, cc-by)
- Funders
- Baden-Württemberg Stiftung
- Bundesministerium für Bildung und Forschung
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, phosphorylated tau, total tau, differential diagnosis of dementia, non-Alzheimer's dementia, diagnostic accuracy, screening biomarkers
- MeSH terms
- Aged, Alzheimer Disease, Enzyme-Linked Immunosorbent Assay, Female, Humans, Luminescent Measurements, Male, Middle Aged, Phosphorylation, ROC Curve, Biomarkers, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
